NCT03896633

Brief Summary

The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
637

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 28, 2018

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 17, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 17, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 28, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 1, 2019

Completed
2.2 years until next milestone

Results Posted

Study results publicly available

June 9, 2021

Completed
Last Updated

May 9, 2023

Status Verified

May 1, 2021

Enrollment Period

9 months

First QC Date

March 28, 2019

Results QC Date

May 14, 2021

Last Update Submit

May 7, 2023

Conditions

GlaucomaOpen Angle or Ocular Hypertension

Outcome Measures

Primary Outcomes (1)

  • Intraocular Pressure (IOP)

    6 weeks

Other Outcomes (1)

  • Change in Intraocular Pressure (IOP)

    6 weeks

Study Arms (2)

Azopt 1% ophthalmic suspension

ACTIVE COMPARATOR

Ophthalmic suspension

Drug: Azopt 1%

Brinzolamide 1% ophthalmic suspension

EXPERIMENTAL

ophthalmic suspension

Drug: brinzolamide 1% ophthalmic suspension

Interventions

brinzolamide 1% ophthalmic suspensionDRUG

brinzolamide 1% ophthalmic suspension

Also known as: brinzolamide
Brinzolamide 1% ophthalmic suspension
Azopt 1%DRUG

Azopt 1%, RLD

Also known as: brinzolamide
Azopt 1% ophthalmic suspension

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and females 18 years of age or older,
  • diagnosed with primary open-angle glaucoma or ocular hypertension.

You may not qualify if:

  • Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma,
  • ocular hypertension.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Various

Bridgewater, New Jersey, 08807, United States

Location

MeSH Terms

Conditions

GlaucomaOcular Hypertension

Interventions

brinzolamide

Condition Hierarchy (Ancestors)

Eye Diseases

Results Point of Contact

Title
Daniel Donatello
Organization
Bausch & Lomb
Daniel.Donatello@bausch.com
5853385306

Study Officials

  • Lindsey Mathew

    Bausch Health Americas, Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2019

First Posted

April 1, 2019

Study Start

February 28, 2018

Primary Completion

November 17, 2018

Study Completion

November 17, 2018

Last Updated

May 9, 2023

Results First Posted

June 9, 2021

Record last verified: 2021-05

Locations

US(1)